Baum Jordan E, Zhang Pan, Hoda Rana S, Geraghty Brian, Rennert Hanna, Narula Navneet, Fernandes Helen D
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.
Cancer Cytopathol. 2017 Jun;125(6):398-406. doi: 10.1002/cncy.21844. Epub 2017 Mar 8.
Minimally invasive diagnostic procedures such as needle-core biopsy and fine-needle aspiration provide adequate material for molecular analyses. Advances in precision oncology are trending toward the interrogation of limited amounts of genomic material to guide clinical and therapeutic decisions. The aim of this study was to investigate the minimum cellularity needed on cytologic smears for the identification of clinically relevant variants with next-generation sequencing (NGS).
Thirty cases of cytologically diagnosed, resection-proven primary lung adenocarcinoma were identified. Nineteen of the 30 cases were known to harbor actionable variants. One Diff-Quik (DQ)-stained slide and 1 Papanicolaou (Pap)-stained slide were selected from each case. Cases were categorized as containing fewer than 100 tumor cells, 100 to 500 tumor cells, or more than 500 tumor cells. NGS was performed on the Ion Torrent platform.
NGS was successfully performed on all cell blocks and on 90% of the smears. Paired DQ and Pap smears showed similar cellularity, and cases that differed in cellularity were within 1 category of each other. The cases with more than 100 tumor cells had a 93% success rate; this was significantly different from the situation for cases with fewer than 100 tumor cells, which were successfully sequenced only 67% of the time. Overall, NGS was able to provide clinically relevant information for 83% of DQ smears and for 90% of Pap smears tested.
The data show a significantly higher likelihood of successful NGS with cytologic smears with more than 100 tumor cells. There was a trend for a higher NGS success rate with Pap smears versus DQ smears. Cancer Cytopathol 2017;125:398-406. © 2017 American Cancer Society.
诸如针芯活检和细针穿刺等微创诊断程序可为分子分析提供足够的材料。精准肿瘤学的进展正趋向于对有限数量的基因组材料进行检测,以指导临床和治疗决策。本研究的目的是调查在细胞涂片上识别具有临床相关性的变异所需的最低细胞数,以便进行下一代测序(NGS)。
确定30例经细胞学诊断、手术切除证实的原发性肺腺癌病例。30例中有19例已知存在可操作的变异。从每个病例中选取1张Diff-Quik(DQ)染色玻片和1张巴氏(Pap)染色玻片。病例被分为含有少于100个肿瘤细胞、100至500个肿瘤细胞或多于500个肿瘤细胞。在Ion Torrent平台上进行NGS。
所有细胞块和90%的涂片均成功进行了NGS。配对的DQ和Pap涂片显示细胞数相似,细胞数不同的病例彼此相差不超过1个类别。肿瘤细胞多于100个的病例成功率为93%;这与肿瘤细胞少于100个的病例情况有显著差异,后者仅67%的时间能成功测序。总体而言,NGS能够为83%的DQ涂片和90%的测试Pap涂片提供临床相关信息。
数据显示,肿瘤细胞多于100个的细胞涂片成功进行NGS的可能性显著更高。Pap涂片的NGS成功率有高于DQ涂片的趋势。《癌症细胞病理学》2017年;125:398 - 406。© 2017美国癌症协会。